Pemphigus Vulgaris:治療薬市場動向2014(市場規模、グローバルAPIメーカー、第Ⅲ相試験)

◆英語タイトル: Pemphigus Vulgaris Market Analysis, Global API Manufacturers and Phase III Pipeline Assessment, 2014
◆発行会社/調査会社:DelveInsight
◆商品コード:DIIR2014419
◆発行日:2014年版(※最新版はお問い合わせください)
◆調査対象地域:グローバル
◆産業分野:製薬
◆ページ数:75以上
◆レポート言語:英語
◆レポート形式:PDF
◆納品方式:Eメール
◆販売価格オプション(消費税別)
Single UserUSD2,000 ⇒換算¥222,000見積依頼/購入/質問フォーム
Site Price(同一国内共有可)USD4,000 ⇒換算¥444,000見積依頼/購入/質問フォーム
Enterprise Price(複数国内共有可)USD6,000 ⇒換算¥666,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらで、ご購入に関する詳細案内はご利用ガイドでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日~2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送いたしますので、請求書発行日より2ヶ月以内に銀行振込にて支払をお願いします。(振込先:三菱東京UFJ銀行/京橋支店/H&Iグローバルリサーチ株式会社)
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はDelveInsight社の日本における正規販売代理店です。同社発行の市場調査資料のご購入、委託調査サービスに関するお問い合わせは弊社までお願い致します。
DelveInsight社の概要及び新刊レポートはこちらでご確認いただけます。

★グローバルリサーチ資料[Pemphigus Vulgaris:治療薬市場動向2014(市場規模、グローバルAPIメーカー、第Ⅲ相試験)]についてメールでお問い合わせはこちら
*** レポート概要(サマリー)***

DelveInsight’s, “ Pemphigus Vulgaris- Market Analysis, Global API Manufacturers and Phase III Pipeline Assessment, 2014”, report provides comprehensive insights about phase III pipeline drugs and marketed drugs across the indication. A key objective of the report is to establish the understanding for API Manufacturers for marketed and Phase III pipeline drugs across the different countries and regions. While the leading brands, companies and chemicals are considered thoroughly, the report also provides details on the drug master filings across the US, Europe and Asia specifically China and India. The research, analysis also presents the global sales forecasts data till 2015. The report is also giving insight about the patent and exclusivity details of all the drugs across the indication.

Data Sources

The report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by DelveInsight team of industry experts.

Secondary sources information and data has been collected from various printable and non-printable sources like search engines, News websites, Government Websites, Trade Journals, White papers, Magazines, Trade associations, Books, Industry Portals, Industry Associations and access to available databases.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.


• A snapshot of the global Market therapeutics scenario for Pemphigus Vulgaris.
• A review of the marketed products under prescription for Pemphigus Vulgaris, regulatory information and marketing status.
• Coverage of global patent coverage and detailed commentaries on the US patent challenges.
• Graphical representation of investigational products for patent expiry and market exclusivities across the globe.
• Product profiles for marketed products for Pemphigus Vulgaris with complete description of mechanism of action, therapeutic class, target, route(s) of administration and chemical details.
• Coverage of API Manufacturers for Pemphigus Vulgaris drugs in the United States, Europe and Asian Regions with location details.
• Coverage of Regulatory filings in the US, Europe, and Asia specifically India and China for Pemphigus Vulgaris drugs.
• Coverage of Route of Synthesis of Active Pharmaceutical Ingredient associated with Pemphigus Vulgaris drugs.
• Coverage of Pemphigus Vulgaris Phase III pipeline products featuring sections on product description, mechanism of action, Chemical details and research & development progress.
• Coverage of the United States Drug Master File (US DMF) available for Phase III Pipeline Drugs.
• Key discontinued Marketed products.
• Global Sales Figure from 2011-2015.

• Evaluate the marketing status and exclusivity details of Pemphigus Vulgaris key products to exploit opportunities for generic drug development opportunities.
• Identify and understand important and diverse types of therapeutics under Phase III development for Pemphigus Vulgaris.
• Design effective counter-strategies to gain competitive advantage by identifying the key patent expiry details and exclusivity with respect to Pemphigus Vulgaris.
• API intelligence over marketed drugs for Pemphigus Vulgaris and gaining primary intelligence over active ingredients manufacturers across the globe.
• API intelligence over leading Phase III pipeline drugs.
• Develop and designstrategies by identifying the API manufacturers for Phase III pipeline products to enhance and expand business potential and scope.
• Understanding the scope of the Phase III Drugs with nil regulatory filings.
• Understanding the chemical route of synthesis of approved drugs for Pemphigus Vulgaris.
• Uncovering opportunities in the rapidly growing the US markets.

*** レポート目次(コンテンツ)***

• Indication Overview
• Marketed Drugs Assessment
• Marketed Details of Drugs by Application Type
• Marketed Details of Drugs (NDA) by Marketing Status
• Marketed Details of Drugs by Patent Expiration Timeline
• The Active Pharmaceutical Ingredient (API) Manufacturers Assessment
• The API Manufacturers by the United States Drug Master File (US DMF) Status
• The API Manufacturers by the US DMF Status (Drug Specific)
• The Active Pharmaceutical Ingredient (API) Manufacturers Assessment for Phase III Pipeline Drugs
• The API Manufacturers by the US DMF Status (Drug Specific)
• Drugs Market Data and Forecasted Sales Figures (2011-2015)
• Marketed Drugs Information
• Drugs Description
• Route of Synthesis
• Global Active Pharmaceutical Manufacturers
• Approval Status
• Patent and Exclusivity Details
• Company Overview
• Phase III Drugs Information
• Phase III Drugs Description
• The United States Drug Master Filings (US DMF)
• Discontinued Drugs Information

Pemphigus Vulgaris Therapeutic Market, US, Marketed Drugs by Application Type, 2014
Pemphigus Vulgaris Therapeutic Market, US, Marketed Drugs by Marketing Status, 2014
Pemphigus Vulgaris Therapeutic Market, US, (Year), 2014
Pemphigus Vulgaris Marketed Drugs, API Manufacturers by US DMF Status, 2014
Pemphigus Vulgaris Marketed Drugs, US DMF Status Drug Specific (Number), 2014
Pemphigus Vulgaris Phase III Pipeline Drugs, US DMF Status Drug Specific (Number), 2014
Pemphigus Vulgaris Therapeutic Market, Global Sales (in million USD), 2014
Pemphigus Vulgaris Marketed Drugs, API Manufacturers, Global, 2014
Pemphigus Vulgaris Phase III Pipeline Drugs, United States Drug Master File (DMF), 2014
Discontinued Drugs for Pemphigus Vulgaris, 2014

Pemphigus Vulgaris Therapeutic Market, US, Marketed Drugs by Application Type (%), 2014
Pemphigus Vulgaris Therapeutic Market, US, Marketed Drugs by Marketing Status (%), 2014
Pemphigus Vulgaris Therapeutic Market, US, (Year), 2014
Pemphigus Vulgaris Marketed Drugs, API Manufacturers by US DMF Status (%), 2014
Pemphigus Vulgaris Marketed Drugs, US DMF Status Drug Specific (Number), 2014
Pemphigus Vulgaris Phase III Pipeline Drugs, US DMF Status Drug Specific (Number), 2014
Pemphigus Vulgaris Therapeutic Market, Global Sales (in million USD), 2014
Pemphigus Vulgaris Marketed Drugs, Patent/Exclusivity Expiry (Year), 2014

*** 掲載企業 ***

Roxane Laboratories, Inc.
Pharmacia & Upjohn, Inc.
Merck & Co., Inc.
Parke-Davis
Pfizer Inc.
Merck Sharp & Dohme Corp.
Sandoz Inc.
Panray Corporation
UCB, Inc.

*** レポートのキーワード ***

Pemphigus Vulgaris、医薬品、治療薬、規模、販売量、医薬品有効成分(API)メーカー、第Ⅲ相試験、製薬

*** 免責事項 ***
https://www.globalresearch.co.jp/disclaimer/


※おすすめ調査資料
※当サイト上のレポートデータは弊社H&Iグローバルリサーチ運営のMarketReport.jpサイトと連動しています。
※当市場調査資料(DIIR2014419 )"Pemphigus Vulgaris:治療薬市場動向2014(市場規模、グローバルAPIメーカー、第Ⅲ相試験)" (英文: Pemphigus Vulgaris Market Analysis, Global API Manufacturers and Phase III Pipeline Assessment, 2014)はDelveInsight社が調査・発行しており、H&Iグローバルリサーチが販売します。


◆H&Iグローバルリサーチのお客様(例)◆


※当サイトに掲載していない調査資料も弊社を通してご購入可能ですので、お気軽にご連絡ください。ウェブサイトでは紹介しきれない資料も数多くございます。
※H&Iグローバルリサーチ(登録第5864124号)及びH&I(登録第5783645号)はH&Iグローバルリサーチ株式会社の商標です。